Los Angeles, California 90095

  • Macular Degeneration


The purpose of this study is to determine whether microplasmin given by intravitreal injection is effective and safe for the treatment of wet age-related macular degeneration (AMD) in patients who have focal vitreomacular adhesion (VMA)

Study summary:

The human vitreous gel undergoes progressive liquefaction with age. Concurrent with the process of vitreous liquefaction, there is a weakening of the adhesion at the vitreoretinal interface between the cortical vitreous gel and the inner limiting lamina. Posterior vitreous detachment (PVD) is a separation of the cortical vitreous get from the inner limiting lamina. PVD is usually a sudden event during which liquefied vitreous from the center of the vitreous body bursts through a hole in the posterior vitreous cortex and then dissects the residual cortex gel away from the inner limiting lamina. If there is residual vitreoretinal traction around the break, this process may induce a tear in the retina that can in turn result in rhegmatogenous retinal detachment, macular hole, or cystoid macular edema. The importance of the vitreous in the progression of diabetic retinopathy may also extend beyond tractional considerations. For example, it is believed that the vitreous serves as scaffolding for new vessel formation and may also contribute to molecular imbalances that lead to retinopathy progression. Therefore, total PVD, by releasing vitreoretinal traction as well as other potential mechanisms, may be beneficial in various vitreoretinal diseases such as neovascular AMD. Vitreomacular adhesion (VMA) in exudative (wet) AMD may be associated with poor prognosis in patients with AMD. This trial is primarily aimed at showing that release of VMA can be induced by microplasmin, a proteolytic enzyme, in patients with wet AMD, and that microplasmin is safe in patients w/ neovascular (wet) AMD. Secondary endpoint will be assessment of improved AMD outcomes.


Inclusion Criteria: - Male or female subjects aged 50 years or older - Presence of focal vitreomacular adhesion as seen by OCT - BCVA of 20/800 or better in non-study eye - Presence of active choroidal neovascular membrane - Written informed consent obtained from subject prior to inclusion in the trial Exclusion Criteria: - Subjects who have previously received microplasmin - Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes adequate examination or investigation of study eye - Patient with uncontrolled glaucoma including IOP >25 mm Hg - Subjects who have had vitrectomy or retinal detachment or who are aphakic or highly myopic (>8.0 D) in the study eye - Subjects who are pregnant or of child-bearing potential not utilizing an acceptable form of contraception. Acceptable methods include intrauterine device, oral, implanted or injected contraceptives, and barrier methods with spermicide. - Subjects who, in the Investigator's view, will not complete all visits and investigations - Patient who have PDT or any intravitreal injection in the last 10 days. Patients who in the examiners opinion will need intravitreal injection in the next 10 days (apart from microplasmin). - Patients who have participated in an investigational drug trial in the past 30 days.



Primary Contact:

Principal Investigator
Steven D Schwartz, M.D.
University of California, Los Angeles

Rosaleen M Ostrick, MPH, MA
Phone: 310-794-5595
Email: ostrick@jsei.ucla.edu

Backup Contact:

Email: hitchcock@jsei.ucla.edu
Logan Hitchcock, B.S.
Phone: 310-794-5596

Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.